Trials / Completed
CompletedNCT01531023
Treatment of Extended Spectrum Betalactamase Producing Bacteria Causing Urinary Tract Infections in General Practice
What is the Outcome of Treatment of Urinary Tract Infections Caused by Bacteria Producing Extended Spectrum Betalactamase in a Primary Care Setting?
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 168 (actual)
- Sponsor
- University of Oslo · Academic / Other
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The prevalence of extended spectrum beta-lactamase (ESBL) producing bacteria found in urine sample cultures has been increasing over the past decades. The study hypothesis is to assess the clinical and microbiological outcome of pivmecillinam treatment of ESBL producing E. coli and K. Pneumoni, as well as to observe the clinical and microbiological outcome of the same group of bacteria treated with other antiinfectious agents. Samples are gathered in primary care setting.
Conditions
Timeline
- Start date
- 2013-04-01
- Primary completion
- 2016-09-01
- Completion
- 2016-09-01
- First posted
- 2012-02-10
- Last updated
- 2016-10-31
Locations
7 sites across 1 country: Norway
Source: ClinicalTrials.gov record NCT01531023. Inclusion in this directory is not an endorsement.